Intermittent Fasting as a Novel Treatment Approach for Patients Treated with Atypical Antipsychotics

Since the 1950’s, many individuals suffering from major psychotic illness have been able to substantially reduce their symptom burden with antipsychotic medications. 

The past few decades has experienced a transition away from first generation dopamine D2 receptor agonists towards second generation antipsychotic medication (SGA) seratonin 5H7-2a antagonists, referred to as “atypical” antipsychotics, examples being Clozapine and Olanzapine. These atypical antipsychotics are different in mechanism and unlike first generation antipsychotics (FGA), they are less likely to cause parkinsonian symptoms and have an increased efficacy in treating negative symptoms.  Read more>>>>>>>>>>>>>